Consultation record

Submissions accepted in part — page 5

Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.

Submissions

390 documents · page 5 of 13

Table 1. Submissions with this disposition, on this page.

Reference	Consultation	Respondent	Point raised
DRAFT-MELANOCORTIN/002	Draft scoping review: melanocortin receptor agonists	Dr Kolawole Isaksen-Balogun	The axis of the forest plot exaggerates a small difference
DRAFT-MELANOCORTIN/009	Draft scoping review: melanocortin receptor agonists	Anselm Mountstephen	References should carry a persistent identifier for every cited source
DRAFT-SEARCH-STRAT/003	Draft search-strategy template for the synthesis series	Thaddeus Isaksen-Balogun	The conditions for upgrading observational evidence are too permissive
DRAFT-SEARCH-STRAT/007	Draft search-strategy template for the synthesis series	Dr Melisande Kirkpatrick-Ola	Preprints and conference abstracts are excluded categorically
DRAFT-SEARCH-STRAT/009	Draft search-strategy template for the synthesis series	Anselm Mountstephen	The database set omits sources relevant to the compounds in scope
DRAFT-SEARCH-STRAT/012	Draft search-strategy template for the synthesis series	Dr Ivo Quintanilha	Automated assistance in screening should be disclosed and validated
DRAFT-SEARCH-STRAT/013	Draft search-strategy template for the synthesis series	Dr Kolawole Isaksen-Balogun	No information-size criterion is applied before an interval is judged
DRAFT-SEARCH-STRAT/019	Draft search-strategy template for the synthesis series	Dr Odalys Thorsby-Nakamura	Non-randomised evidence is admitted for harms and excluded for benefits without a stated basis
DRAFT-PRINT-AND-AR/003	Draft print and archival format for Institute documents	Vittoria Ylönen	A declaration is made on appointment and never refreshed
DRAFT-PRINT-AND-AR/006	Draft print and archival format for Institute documents	Ms Rhiannon Okoye-Vandergraaf	A four-week window is too short for a respondent without institutional support
DRAFT-PRINT-AND-AR/010	Draft print and archival format for Institute documents	Dr Georgiana Mountstephen	Funding should not be accepted from any party the Institute assesses
DRAFT-PRINT-AND-AR/011	Draft print and archival format for Institute documents	Professor Bartolomeu Nkosi-Lindegaard	A party criticised in an assessment should have a right of reply
DRAFT-PRINT-AND-AR/014	Draft print and archival format for Institute documents	Dr Rurik Haverkamp-Diallo	The materiality threshold for a declarable holding is set too high
DRAFT-PRINT-AND-AR/016	Draft print and archival format for Institute documents	Quentin Whitmarsh-Obi	References should carry a persistent identifier for every cited source
DRAFT-CERTAINTY-IN/001	Draft certainty index	Eamon Sandringham-Adu	References should carry a persistent identifier for every cited source
DRAFT-CERTAINTY-IN/003	Draft certainty index	Dr Zdenka Nyquist-Obiora	The anchor outcome for an indication is not the outcome a decision turns on
DRAFT-CERTAINTY-IN/004	Draft certainty index	Dr Marisol Dunmore-Ekpo	A document is split across parts at a point that separates a claim from its support
DRAFT-CERTAINTY-IN/010	Draft certainty index	Yolanda Norrington-Bhatt	The front matter delays the reader from reaching the assessment
DRAFT-CERTAINTY-IN/014	Draft certainty index	Dr Vasilisa Immelmann	The series scope is drawn widely enough to absorb documents that belong elsewhere
DRAFT-CERTAINTY-IN/015	Draft certainty index	Dr Oisín Rautavaara	Point estimates are given without an interval
DRAFT-AMYCRETIN-MO/002	Draft monograph: amycretin	Dr Jolanta Uttridge	Storage and reconstitution guidance is given without stating what it rests on
DRAFT-AMYCRETIN-MO/008	Draft monograph: amycretin	Dr Perpetua Haverkamp-Diallo industry	The monograph should reproduce the approved labelling rather than paraphrase it
DRAFT-AMYCRETIN-MO/009	Draft monograph: amycretin	Dr Liesbeth Achterberg	Anti-drug antibody data are omitted
DRAFT-AMYCRETIN-MO/014	Draft monograph: amycretin	Ms Rhiannon Okoye-Vandergraaf	The document is unreadable without specialist training
DRAFT-5-AMINO-1MQ-/005	Draft monograph: 5-amino-1MQ	Dr Zdenka Nyquist-Obiora	The preclinical section is extensive and the clinical section is not
DRAFT-AOD-9604-MON/004	Draft monograph: AOD-9604	Dr Odalys Thorsby-Nakamura	Trials are described as terminated where they completed as planned
DRAFT-AOD-9604-MON/009	Draft monograph: AOD-9604	Dr Henrike Jastrzębska	The analytical section is longer than the clinical assessment it accompanies
DRAFT-AOD-9604-MON/013	Draft monograph: AOD-9604	Dr Liesbeth Nyquist-Obiora	Storage and reconstitution guidance is given without stating what it rests on
DRAFT-CAGRILINTIDE/003	Draft monograph: Cagrilintide	Dr Oisín Rautavaara	Point estimates are given without an interval
DRAFT-CAGRILINTIDE/007	Draft monograph: Cagrilintide	Dr Marisol Dunmore-Ekpo	Trials are described as terminated where they completed as planned

page 5 of 13